Sweden-based Anocca AB has appointed Michael Kalos to its scientific advisory board to help it advance its T cell therapies and vaccines for cancer. Dr Kalos was most recently head of R&D at ArsenalBio Inc, a US cell therapy company. He received his PhD from the University of Minnesota and did postdoctoral training at the Fred Hutchinson Cancer Research Center. His laboratory at the University of Pennsylvania, US, contributed to the development of the CTL019 programme which later became Kymriah.
Anocca AB announced the appointment on 7 April 2022.
Copyright 2022 Evernow Publishing Ltd